BRAF in metastatic colorectal cancer: the future starts now

被引：14

作者：

Orlandi, Armando ^{[1
]}

Calegari, Maria Alessandra ^{[1
]}

Inno, Alessandro ^{[2
]}

Berenato, Rosa ^{[3
]}

Caporale, Marta ^{[3
]}

Niger, Monica ^{[3
]}

Bossi, Ilaria ^{[3
]}

Di Bartolomeo, Maria ^{[3
]}

de Braud, Filippo ^{[3
]}

Pietrantonio, Filippo ^{[3
]}

机构：

[1] Univ Cattolica Sacro Cuore, Dept Med Oncol, Rome, Italy

[2] Sacro Cuore Don Calabria Hosp, Med Oncol, Verona, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

来源：

PHARMACOGENOMICS | 2015年 / 16卷 / 18期

关键词：

BRAF; colorectal cancer; immunotherapy; target therapy; FOLFOXIRI PLUS BEVACIZUMAB; EGFR MONOCLONAL-ANTIBODIES; KRAS MUTATIONAL STATUS; COLON-CANCER; V600E MUTATION; MICROSATELLITE INSTABILITY; 1ST-LINE TREATMENT; RAS MUTATIONS; POOR SURVIVAL; MAPK PATHWAY;

D O I：

10.2217/pgs.15.140

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

BRAF mutations are detectable in about 5-15% of metastatic colorectal cancer (mCRC) patients and represent a clear negative prognostic factor. While in BRAF-mutated (BRAFmt) metastatic melanoma TKI target therapies (BRAF and MEK inhibitor), both alone or in combination, have shown significant efficacy, in BRAFmt CRC single-agent BRAF-inhibitors as well as chemotherapy seem to be ineffective. The critical role of EGFR in CRC and its multiple downstreaming pathways seem to be involved in this lack of response. In recent years, preclinical investigations and retrospective studies slowly increased our knowledge on BRAFmt CRC. This review analyses preclinical data and discusses several clinical trials in order to explore new therapeutic strategies targeting BRAFmt mCRC.

引用

页码：2069 / 2081

页数：13

共 50 条

[31] KRas and Braf: Is a Predictor in Metastatic Colorectal Cancer Patients for Bevacizumab?
Selcukbiricik, F.
Yildiz, O.
Tural, D.
Ozturk, M. A.
Demir, G.
Ozguroglu, M.
Erdamar, S.
Buyukunal, E.
Mandel, N. M.
Serdengecti, S.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S397 - S397
[32] Global BRAF testing practices in metastatic colorectal cancer.
Kopetz, Scott
Grothey, Axel
Ciardiello, Fortunato
Desai, Jayesh
Kim, Tae Won
Maughan, Tim
Van Cutsem, Eric
Wasan, Harpreet Singh
Yaeger, Rona
Yoshino, Takayuki
Gollerkeri, Ashwin
Edwards, Michelle
Lizaso, Montessa Rodriguez
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[33] A novel concomitant NRAS and BRAF mutation in metastatic colorectal cancer
Douik, H.
Sahraoui, G.
Doghri, R.
Charfi, L.
Mrad, K.
ANNALS OF ONCOLOGY, 2023, 34 : S140 - S140
[34] Global BRAF testing practices in metastatic colorectal cancer (mCRC).
Desai, Jayesh
Kopetz, Scott
Grothey, Axel
Ciardiello, Fortunato
Kim, Tae Won
Maughan, Tim
Van Cutsem, Eric
Wasan, Harpreet Singh
Yaeger, Rona
Yoshino, Takayuki
Gollerkeri, Ashwin
Edwards, Michelle L.
Rodriguez Lizaso, Montessa
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[35] Treatment options in BRAF-mutant metastatic colorectal cancer
Bernabe-Ramirez, Carolina
Patel, Rajvi
Chahal, Jaspreet
Saif, Muhammad Wasif
ANTI-CANCER DRUGS, 2020, 31 (06) : 545 - 557
[36] OVERVIEW: HEPATOCELLULAR CARCINOMA - THE FUTURE STARTS NOW
George, Jacob
Robotin, Monica
CANCER FORUM, 2009, 33 (02)
[37] ADOLESCENTS, AIDS, AND HIV - THE FUTURE STARTS NOW
KERR, DL
JOURNAL OF SCHOOL HEALTH, 1989, 59 (06) : 277 - 278
[38] RAS/ BRAF molecular profile in metastatic versus non-metastatic colorectal cancer
Douik, H.
Sahraoui, G.
Charfi, L.
Doghri, R.
Mrad, K.
ANNALS OF ONCOLOGY, 2023, 34 : S151 - S151
[39] Chemotherapies and future directions in metastatic colorectal cancer
Winder T.
memo - Magazine of European Medical Oncology, 2017, 10 (3) : 141 - 145
[40] Future of targeted agents in metastatic colorectal cancer
Burotto, Mauricio
Hartley, Marion L.
Marshall, John L.
Pishvaian, Michael J.
COLORECTAL CANCER, 2012, 1 (05) : 433 - 443

← 1 2 3 4 5 →